| Shania Anglade, | |
|
560 S Lakewood Dr Ste 101, Brandon, FL 33511-5015 | |
| (813) 978-9700 | |
| Not Available |
| Full Name | Shania Anglade |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 560 S Lakewood Dr Ste 101, Brandon, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225600810 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Provider Name | Active Physical Therapy Services, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1225217334 PECOS PAC ID: 0446315816 Enrollment ID: O20090227000075 |
News Archive
The first known attempt to evaluate the sleep patterns of children with Asperper Syndrome (AS), taking into account sleep architecture and the cyclic alternating pattern (CAP), finds that children with AS have a high prevalence of some sleep disorders and mainly problems related to initiating sleep and sleep restlessness together with morning problems and daytime sleepiness, according to a study published in the November 1 issue of the journal SLEEP.
Headlines offer a range of developments from the Romney-Ryan campaign, including reports about its advertising strategy, Ryan's response - or lack of one - to former President Bill Clinton's criticism and a fact check regarding their Medicare policy.
CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).
Varian Medical Systems has received FDA 510(k) clearance for a new radiotherapy treatment planning tool designed to work with the company's market leading Eclipse™ treatment planning software to reduce the amount of time needed for planning advanced treatments.
Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shania Anglade, 13020 N Telecom Pkwy, Temple Terrace, FL 33637-0925 Ph: (813) 978-9700 | Shania Anglade, 560 S Lakewood Dr Ste 101, Brandon, FL 33511-5015 Ph: (813) 978-9700 |
News Archive
The first known attempt to evaluate the sleep patterns of children with Asperper Syndrome (AS), taking into account sleep architecture and the cyclic alternating pattern (CAP), finds that children with AS have a high prevalence of some sleep disorders and mainly problems related to initiating sleep and sleep restlessness together with morning problems and daytime sleepiness, according to a study published in the November 1 issue of the journal SLEEP.
Headlines offer a range of developments from the Romney-Ryan campaign, including reports about its advertising strategy, Ryan's response - or lack of one - to former President Bill Clinton's criticism and a fact check regarding their Medicare policy.
CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).
Varian Medical Systems has received FDA 510(k) clearance for a new radiotherapy treatment planning tool designed to work with the company's market leading Eclipse™ treatment planning software to reduce the amount of time needed for planning advanced treatments.
Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.
› Verified 6 days ago
Michael Miller, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 1320 Oakfield Dr, Brandon, FL 33511 Phone: 727-803-1102 | |
Alison Jussaume, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 Vonderburg Dr, Suite 201, Brandon, FL 33511 Phone: 813-653-1149 Fax: 813-654-6644 | |
Diana Marie Riva, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 206 Ridgewood Ave, Brandon, FL 33510 Phone: 813-662-1060 Fax: 813-662-0530 | |
Kathleen Pici, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 Vonderburg Dr, Suite 201, Brandon, FL 33511 Phone: 813-653-1149 Fax: 813-654-6644 | |
Mrs. Tierra S Momplaisir, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 206 Ridgewood Ave Pediatric Therapy Services, Brandon, FL 33510 Phone: 813-662-1060 Fax: 813-662-0530 | |
Mrs. Dail Wooten Hovey, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 206 Ridgewood Ave, Brandon, FL 33510 Phone: 813-662-1060 | |
Ms. April Fletcher, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 Vonderburg Dr, Suite 201, Brandon, FL 33511 Phone: 813-653-1149 Fax: 813-654-6644 |